Abstract
1Queen’s University, Kingston, Ontario; 2University of Montreal, Montreal, Quebec; 3University of Toronto, Toronto, Ontario; 4University of British Columbia, Vancouver, British Columbia; 5University of Calgary, Calgary, Alberta; 6University of Western Ontario, London, Ontario; 7University of Alberta, Edmonton, Alberta; 8Dalhousie University, Halifax, Nova Scotia; 9University of Manitoba, Winnipeg, Manitoba; 10Laval University, Quebec City, Quebec Correspondence: Dr M Diane Lougheed, Division of Respirology, Department of Medicine, Queen’s University, 102 Stuart Street, Kingston, Ontario K7L 2V6. Telephone 613-548-2348, fax 613-549-1459, e-mail mdl@queensu.ca CommenTAry
Highlights
The Canadian Thoracic Society (CTS) Asthma Committee has reviewed the announcement made February 18, 2010, by the United States Food and Drug Administration (FDA) regarding new safety controls and labelling requirements for long-acting beta-2 agonists (LABAs) for asthma in the United States
Ever since LABAs were introduced in Canada, the 1996 Canadian Asthma Consensus Conference [3], subsequent updates [4,5,6], a perspective on LABAs [7], an evidence-based review [8] and the most recent Consensus Summary [1] have all emphasized the following:
LABAs should only be used as add-on therapy to an antiinflammatory controller in any age group;
Summary
The Canadian Thoracic Society (CTS) Asthma Committee has reviewed the announcement made February 18, 2010, by the United States Food and Drug Administration (FDA) regarding new safety controls and labelling requirements for long-acting beta-2 agonists (LABAs) for asthma in the United States. The 2010 CTS Asthma Management Continuum and Consensus Summary [1] is congruent with the FDA’s recommendations. Ever since LABAs were introduced in Canada, the 1996 Canadian Asthma Consensus Conference [3], subsequent updates [4,5,6], a perspective on LABAs [7], an evidence-based review [8] and the most recent Consensus Summary [1] have all emphasized the following:
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
